Satori Pharmaceuticals, a US-based developer of therapeutics for Alzheimer’s Disease, secured $15m in funding on Thursday from venture capital firms New Enterprise Associates, Prospect Venture Partners and Interwest Partners. The round represents the culmination of the round, the first tranche of which was secured in January last year, bringing Satori’s overall funding to $40m. Early…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
